CINXE.COM

<!DOCTYPE html><html lang="en-US"><head><title>Just a moment...</title><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="robots" content="noindex,nofollow"><meta name="viewport" content="width=device-width,initial-scale=1"><style>*{box-sizing:border-box;margin:0;padding:0}html{line-height:1.15;-webkit-text-size-adjust:100%;color:#313131;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol,Noto Color Emoji}body{display:flex;flex-direction:column;height:100vh;min-height:100vh}.main-content{margin:8rem auto;max-width:60rem;padding-left:1.5rem}@media (width <= 720px){.main-content{margin-top:4rem}}.h2{font-size:1.5rem;font-weight:500;line-height:2.25rem}@media (width <= 720px){.h2{font-size:1.25rem;line-height:1.5rem}}#challenge-error-text{background-image:url(data:image/svg+xml;base64,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);background-repeat:no-repeat;background-size:contain;padding-left:34px}@media (prefers-color-scheme:dark){body{background-color:#222;color:#d9d9d9}}</style><meta http-equiv="refresh" content="390"></head><body class="no-js"><div class="main-wrapper" role="main"><div class="main-content"><noscript><div class="h2"><span id="challenge-error-text">Enable JavaScript and cookies to continue</span></div></noscript></div></div><script>(function(){window._cf_chl_opt={cvId: '3',cZone: "ashpublications.org",cType: 'managed',cRay: '8e744ce47e4ace29',cH: '2kNWNFjCldP5pRiXzQ2eNVdtYcKjfjWfg2Aa1zQU0p4-1732397845-1.2.1.1-fRam.wncf2kYZCDqAVsuJ6qCflF9yYOvxUAWId48vTePTKsHO77dV.b6ZPHhRQJN',cUPMDTk: "\/blood\/article\/doi\/10.1182\/blood.2024025563\/518286\/Zanubrutinib-Obinutuzumab-and-Venetoclax-for-First?__cf_chl_tk=k0Xs_0motkNBNTVdyWw7.RVUIO47_dbq4__l6yhBJHY-1732397845-1.0.1.1-AS62xyMYZN.NcrL_09Aqs8OpE711IDneJ9N.GBTu9fY",cFPWv: 'g',cITimeS: '1732397845',cTTimeMs: '1000',cMTimeMs: '390000',cTplC: 0,cTplV: 5,cTplB: 'cf',cK: "",fa: "\/blood\/article\/doi\/10.1182\/blood.2024025563\/518286\/Zanubrutinib-Obinutuzumab-and-Venetoclax-for-First?__cf_chl_f_tk=k0Xs_0motkNBNTVdyWw7.RVUIO47_dbq4__l6yhBJHY-1732397845-1.0.1.1-AS62xyMYZN.NcrL_09Aqs8OpE711IDneJ9N.GBTu9fY",md: "zNoMUTIy5Vyvf5GWo.pIoBsD1xwPqL7SVgGw5iQOk_U-1732397845-1.2.1.1-i_zZ0gdJznJZ4Sqqi6tZQ..BVQ7O9JNICR2H4b.oUGxrVmAkVmT13N27xknPCC8vhlu2PLXmQbykUzyWsPLs890vS1TNn3TBvQNfLxRYPlDGXHD3HonQ_JuBhVtm4y6KYWG.nV.gGJmvdzGkwL5frUAurU5j59cf027GTdhprncMFjMGjYzyT0lx3xHILb8pYX.tt_LWfX5BtTmQR1H5Knyj549PuT2jG4PhRW9thr6ZWJ2oS8pqEV9Z.4mHPK1pWljbkbT0hLeymAM44F.cC5zLcHDtYfFaj_4HbY7KNdFlFBJX7kLYFAlyhb0aeTyr5lJP7p50BZdqf_hg8BY73AWrRsE8o8T6gNZgU6MxdzLUa._pfPol2AvYrb8Ho3ZEnexbfL..W9prtjibEE2fNVeIFVB9Xm.OAzjiirGcl9U8n3wqO1IGMinHTM4PqjMgwEsSAg6lSzqkwp1scDgK7pRV2j9u6c4fUaKENDEpkQlETIXIunQSjTfK96O1cmhnx6rTufUG3ZSvtAIOV2Otb7iWWNcriEonxa3hWc3S77wxah4BOQjkzIsOCl2p_uvmILqfV008sIbgeMo5Xt_xhBbL3ECwSpn6Wg0eQPTvJZLuLWX4scipaLNazhHBOQx.Timghz2cBlfOh2bkWVFjUDmRNEtGypBqLmYVpH7M0nL9r2lq_xTg6mG5rR5TTB7D_Z2L8YMTBqKCPrb5uNPi_ngydl8X9jp3UAlaq8y_dqWgtbh0R9bWFRjgw1PGJ.1QbMNrs_UerV0lNgq5eW1X49so5Jg8NtbmDoiynWr52U3eBtDJITgay5zeRaP.QOyxnvZjTK4Ma999_1Nl3ha.1sKV87IVF01_S3WY_X24GyT7.JS.f12yqgRz_IjjkqyKCOSIoSy5qrjBQXfyWo5Ai4Dzhxv1035DqBnlQ9V7A0NJe.vaDUxd1qM3hEJ2xCXjyIOpJlXJ0xR68lfUE3JHD7b1SZLApDXf7ZpG5N2HiuPcTs2kcVLFQgD5YznUEbYwZaqmM1yRBBt9Uywp2_K9Ourx6Eh0KTRdRqJVEd3s3DuZoOWGvZ23IVjyJMVoFgk9xjKWIiIVNzCb_TKTf.h7S_C2Swg_YXo8XSkw2w46h6WtNq9n84JeVBngeUZr2G1uwAVyZFBOFoxXZtcMmV0uY7VJjnMYIS9Ec5iQif6Vn0X_jSF8OSUmm9quFyJe1qIvhFy9LDwpTldK50NEPn8KGdMwbVVv4hvaQZCeP7xDc17j0X0ekPIu8t_H59HyfjCvJq7Z33IitJ1ZMhXejvHM_GksGNZ6raTgK1Y2quxwH25.HAeZRZuIEa.OubwokLOWCUubgJDsNN9VdoNAEebKaSSGkyUUsD.kgDxwPqrXWSVTZpTFnh5G6sse1TESj374LrCLflIqQZHGqWtUV5u3Ig9UAKR.exFiNUJk0LVgOqmD5wC_TRi97DHkRfLLAZRVtGRbwc1NzEaB9sus5ajUaVKc4W68LL9zEWj1vpnd.6ZBRmYSv3U_Ltzg42iTr5yPoqBL84X9vKlih9vRf8gYxGZgogoWdNyaXcKBBIWDnhjDeYSnPEis_ezkHc0lD4n.NJMAHM6uAlBOr2UO8B0ktJyRTpbqU4hSy2LhyGLW63kW91gO4Z4uo8xQ2cihQ9WZAw.lQHRj0ahy9qAUk0kgLTzDkLW4OoyLj3eOKfFJsXoTtK9WWTc0K5bkKzkvT3l0vfcJ5ESY5nACiPZY2OgOqi5N.nIi0OsPs6cCihx5SDExvGdK6E8e.6vfcWwbJk8JzMnyn4gQJ0nVDIW5CQ3xxOwFO.aa5ZCVNilgJFEgbpOBJQr1JDE5aNE2MJHNxxnu68uH.4UX.lnLw6NJdzKsBLOBD9Bp1AfZyNTyX_MKQ1jH4fWi3oPl99UNRsYur_Wfpy_c3o7KF6f2OIqZqDIWOJ0b4aD1m9aqDdR9LddjI8FJRrFgzNqKXZG6H5eTssE5IErdqwYpFncrxlFStf2KHGba_inkJyyckEp_BfQwEZ0zrQtyYdXIRP0c8Ec2HMB.Onp7cTcnvO6GQBc418_iVY_OwAubSYEBosAhcuvCDNozNbTtmKqrkH12lYV8ocMtdnbWouzAv0L3eRUOf6PJmPzMMwR9cULV56WbebHF5ElZDRhg3KehtvttCyeSCoLwyqIdcaqoR2NrRFTex1f8a3DK7p1mGnyHoLX5hxg.9mZTZPvpPtsAbgb.2NCQWye6OIwVWlaKr9s9JQVaQUi1lDjDrQar3zlbc_0_F79t0.yw6rJnJV9_B7bXPZldnkkqjF.5HyyIrIFD3nPbk9Y0j8YLocAvyA18jHqKM6l3Wl3.ehow2WZIi2cNfmj5RT1lrgGSB3jta.q1R4B7bYhXChj732OvwPLNiOg3xb43_eALOtfTZTUV3MjK6I1m.B0.6LfQlQQa9ohYWpGYjJR2swU6n.mUqTtbb8CKQzMfZqecGJcApSxMMOPYuX7ZksJLDNHNaiyb85jGZUmabpNM3bgsYpq13fNv80ZUb9DDFyExSsMf4OWL5zNafLrnQokgBDYYMJyPjTawMlO.EAvjD320B.gDUkoO3tTrTWJa4brSxc_k4TmQ3.g74oJuJSzjfXLmZcPB_tM4brQP04h_9zsJvoVJauLD7_T5ia5x1JUuxXjYMNhahuTaDJtJBEiHvz3BCykGgz9ycVRPTCKL35xIusRBr6HiZrRBdimwxfwq04fmpF8an8Yw5ZXDXnmfaTubjWnWnsKO3dFqyTHVkv2FUbrnA3gEi14Q400Q2OeoYycMxoqdZyRQSXWdUCMEkQ.vH91aaQItblStIXqECjCgnN50J6ag752QCpBgpx5hyEjZONBkdYVXDYzaFmnpd76gjKu1PyNnthIvrJoGXD4GXl39Z65kUkuWG.ahBV99EoIzE2NJKqeYESfhZcailorpC8KwroSt0kCIkq3AmY8RYIxAzG3w52768kIVhl42wZofqQZyQM74kSaCWo682gnH8K7DMWGTxflJcVg_OeFip9kvYQZTDxbS9wALb7ZNBHRCndlTbpSIOh1eCHkldcXzAO3zgzXzuHNJkvaDHJKsT9UYM9DF7dI6gIf3dp_A.TzWsUD3nCujd7rdqs0bxzCs46951V3WdIn6V8s_KnuhFB6_old5SagroYpueYE",mdrd: "Et_xoDUAGlkNnANpNFIxfKBXiuS.ZuL9o9f.K8q_4sI-1732397845-1.2.1.1-oyk0DAng8CsHbuWi7y1x6zyRSplPYaWwfDs5F2txYcpCIbq5HtZVCkR1kbajIDfXfO.20XVh8jIF3waplzepO0OOuDOOwnnhraS0QHS8BSCsvRzxWGFWeyuNwZ6EIwlFShJ2P_PsgzOuFKJTgGqOKWzJKG7m1EpJjH0mmbysl1E.KV9.TGw7GbttXpiQ2sw1Wo9K0GoD6XOe64pERvpjHgHof.36j4JQD5U.jHDjBDMk_AwgVH2g8XD2BWCrhDuEO6qmvVq8QQEBRkXSZT2ac7Slsq8331f0gNGIJYBC8.sILRR.X17YRThS7zcFVjHr23Wrtkuege9DuYp8oKgjWHg39H2EvuJWuvx6eqYnG8BVoIbR.N6tzjtmsFc2OejdcaklsZxSRlbADzbqFav.9RNNpLgYIVzWA3WaxZBdUSgr_iLGYH9hTYRAU8axt2OSszpKB67Tl.4qMI2oXS0BHyzAW499A5lThBVapY1VBeylVSBJaN3pOB0GEEoXQ8qLjW8Akjap0CP4QWFFQ4v.PwoDc1AvHzZcFhvv3amZn7H7gxfaKfu8b1oIHXLIa0i7k1aRI.63xsshw1qFKngoC5ZX32jyImy9fu9.4gcHfipQIhBy2WICUj2HATHhlVAVARW4sXHOGPpt3JUk0r3SVhfpe6P__5uEV32M.yjk9CnMQVhL9Iu4vKuGw._jnfxSDihFE8BNFA3kMX1Wy9dwGmgSSExPL9BsjKpmiFvtHKBQS79Xz__a0KrLTMdWWjV2fitCXhA_0M1_N_QviGV1v3F8xmfpiJCP9xxvzmMhJx83Eat8MgUQFsGonyVOcInM.yxiUW5avDi.tgB5ESd6Rhz3poCZtM1BzELbC2UwX3HKSEBYwH6farAjOMlCeCLt8WVN21fKf2ZtpfkXz.QOdfF6NUZtII0bO.oDVDFesR19G2wep7yi3U9ilpecIN4WgBxhujOvpGKF4t2N7Km2Wn1JGYptM7FbhASlbdc2k8rlU3.3dNXPDyMy6EaliW7WLQB1yNDlLe8yokzBSdgl6YJ7JmPaxo7pc0KIrVLcljtFZNZJ5j0eL2Lxgx4tB8CUwqmaXeSSDM3dD_rucdze147uj3aBaD89yFcKKnoBqpsWskrzmcnYmHC1oYizOMSAIF7Yx9.Gq2t03zI052e.2jXKdx4PJdj_yMy4zh9xNOkq16CiHM5MEqiErv_FLf4y_YEo.ZuKdvVTrBYHPYdNkxKimDafhFdG_Kx7FcEGg.WSB5F5aw11MAf87zQAPxjiOqwF84BwaEFKDNpIxkomY6dQkR413D.hG9QyJR6pzyS3onS6rD7j6pAoYPUca8ecHeyKaoQfH8bPElX2.7nsYHbk_xWFxswmco73EtITBVKdV9dmR71zvTCJ0a.y0i0ZZ2SR3CsbdiDQXCv51HQdXnB7F_D0tF4rutGOoJXsRHACGT5Ge3EhECdkhfD53hgyjiJwDKQdaK0ipNcVD3DtzDC6WYjt3O6C8ukt6H0VegsJr_9uI3AQYBv9ZJ58_IxmKdkmkaKbZSPqsEK6sKbQgaefpmWavjjgux78GdvKc0cXUk35CCnwJERiwhPno.oWl7XPOgMKkcDXfrBEQpKmK1Ok8wTJBG8ZmXX9nny9UAE2yXQ6FaqDkbsB92NxXbkdf._q9z6SUFmrVQGyBSCIzywdjOh3MbsZZEhQhWIVavZi23xvTuttHMv4flc2dumklrHpF1zD9cwVhwnBFclEKJnVWQ3pOYDxIdouOlmUp7R9xx8DZixqm4zbHzI4c_ZmUGganF3pJBgin0g5Q7YitWTXgfjBkWKfzOkSqb0g2ZvrHL6FgqHMV3YNic.OzCRUUD88IkdvCY_qjAHiTddsxigvu6X7eGfbhjgEnAPcMq.Q_OnbWVBIB6AYZsD4_E39Gz3YyoJuMm8Ft0YsnRxpruu2VXBJr7xrl5ZQidPyHA3stopCC95n3.FVjQRyG7lj"};var cpo = document.createElement('script');cpo.src = '/cdn-cgi/challenge-platform/h/g/orchestrate/chl_page/v1?ray=8e744ce47e4ace29';window._cf_chl_opt.cOgUHash = location.hash === '' && location.href.indexOf('#') !== -1 ? '#' : location.hash;window._cf_chl_opt.cOgUQuery = location.search === '' && location.href.slice(0, location.href.length - window._cf_chl_opt.cOgUHash.length).indexOf('?') !== -1 ? '?' : location.search;if (window.history && window.history.replaceState) {var ogU = location.pathname + window._cf_chl_opt.cOgUQuery + window._cf_chl_opt.cOgUHash;history.replaceState(null, null, "\/blood\/article\/doi\/10.1182\/blood.2024025563\/518286\/Zanubrutinib-Obinutuzumab-and-Venetoclax-for-First?__cf_chl_rt_tk=k0Xs_0motkNBNTVdyWw7.RVUIO47_dbq4__l6yhBJHY-1732397845-1.0.1.1-AS62xyMYZN.NcrL_09Aqs8OpE711IDneJ9N.GBTu9fY" + window._cf_chl_opt.cOgUHash);cpo.onload = function() {history.replaceState(null, null, ogU);}}document.getElementsByTagName('head')[0].appendChild(cpo);}());</script></body></html>